Multiple Sclerosis

We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.

In an educational symposium entitled, "The Evolution of Multiple Sclerosis Treatment: The Role of the Managed Care Pharmacist," Kristen Helms, PharmD, and her 2 colleagues discuss how treatments for multiple sclerosis (MS) have evolved over the past 2 decades, explore the novel and emerging therapeutic strategies for MS, and cover strategies to improve medication adherence for the chronic disease.